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Background. Aspirin is effective at reducing the cardiovascular event rate in defined patient groups. The introduction of
antiplatelet therapies other than aspirin and the concept of aspirin resistance have led to critical reappraisal of current
treatment. This review aims to clarify the evidence for aspirin resistance in patients with atherosclerosis.
Methods. Medline search was performed to identify publications concerned with antiplatelet effects of aspirin and failure of
aspirin therapy. Manual cross referencing was also performed.
Results and conclusion. Wide variations in the rate of aspirin resistance (5.5–75%) have been reported. The lack of
consensus on an appropriate definition and the number of different tests used to investigate aspirin resistance needs to be
addressed. There are few studies where the primary aim was to document aspirin resistance or aspirin non-response. Further
work should aim to investigate if aspirin resistance is clinically important and, if it is, what treatments may be beneficial to
the at risk patient.
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Introduction
Aspirin is commonly used to reduce the risk of
ischaemic events in patients with cardiovascular
disease. Aspirin inhibits platelets by irreversibly
binding to cyclooxygenase and blocking the synthesis
of thromboxane A2. However, patients treated with
aspirin still suffer ischaemic events,1 and laboratory
assessment of platelet function reveals persistent
platelet aggregation despite regular aspirin therapy
in a significant proportion of patients at high risk of
ischaemic events.2 The concept of aspirin resistance
and aspirin non-response has highlighted an area
where current antiplatelet treatment may be subopti-
mal. This collective review attempts to explain the
definitions and mechanisms of aspirin resistance, to
highlight studies of aspirin resistance and to suggest
how deficiencies in our current understanding of this
problem may be addressed.
Methods
Medline search from January 1966 to January 2003 was
performed using the terms ‘aspirin’, ‘platelet’, ‘platelet
aggregation inhibitors’, to identify publications con-
cerned with antiplatelet effects of aspirin. The terms
‘failure’, ‘resistance’, and ‘non-response’ were used to
identify articles referring to aspirin resistance. Refer-
ence lists of major articles were also reviewed for
further relevant publications.
Results
Aspirin and alternative antiplatelet medications in
cardiovascular disease
Aspirin has been shown to be effective in both primary
and secondary prevention of adverse cardiovascular
events. Compared with placebo, aspirin treatment in
middle aged men has been reported to reduce the risk
of a first myocardial infarction (MI) by 44% over a 5-
year period3,4 and has also been shown to reduce
mortality in patients following MI by 23% when
used in conjunction with thrombolytic therapy.5
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Meta-analysis of randomised trials involving antipla-
telet therapy in .100,000 patients and controls have
demonstrated a 25% reduction in vascular death, MI
and stroke in patients at high risk of vascular
complications, with aspirin being the most widely
studied antiplatelet agent.6 Antiplatelet therapy has
also been shown to confer a 48% reduction in vascular
graft and arterial occlusion.7,8 Aspirin exerts its
antiplatelet effect by irreversibly acetylating the
serine-530 in the active site of the cyclooxygenase 1
(COX1) enzyme and deactivating it for the life of the
platelet (Figs. 1 and 2). This deactivation leads to
inhibition of thromboxane A2 (TXA2) production, a
potent platelet agonist.9,10
While the benefits of aspirin are widely accepted its
side effects and the fact that a proportion of patients
experience ischaemic events despite aspirin therapy
has led to the development of other antiplatelet agents.
From clinical observation recurrent ischaemic events
despite treatment with aspirin is not uncommon. Of
10,948 patients suffering a non-ST elevation acute
coronary syndrome enrolled in the PURSUIT (Platelet
IIb/IIIa in Unstable angina: Receptor Suppression
Using Integrilin Therapy) trial, 63.8% had been taking
Fig. 1. Pathways of thienopyridine and COX-1 mediated inhibition of platelet activation. COX1 inhibition inhibits formation
of TXA2, but does not inhibit feedback from TXA2 already generated. Thienopyridine blockade of ADP receptor inhibits both
exogenous ADP dependent platelet activation and the feedback effect of ADP released from platelet granules.
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aspirin for 2 weeks prior to infarction.1 Relative or
complete resistance to the antiplatelet effect of aspirin
might have contributed to the poor outcomes seen in
this patient group.1
Alternative antiplatelet medications have been
shown to provide benefits with regard to reduction
of recurrent events compared to aspirin.11 Thienopyr-
idines, such as ticlopidine and clopidogrel, inhibit
platelets by selectively and irreversibly binding to the
adenosine diphosphate (ADP) receptor on platelet
membranes thus blocking the ADP dependent acti-
vation of the Glycoprotein IIb/IIIa (GP IIb/IIIa)
complex which is the major receptor for fibrinogen
on the platelet surface12 (Fig. 1). Ticlopidine has been
shown to reduce the rate of recurrence of transient
ischaemic attacks and stroke in patients in whom
aspirin therapy has failed clinically.13 Clopidogrel, in
two large prospective randomised trials,11 achieved a
7–8% decrease in relative risk of recurrent stroke, MI
or vascular death over aspirin when taken alone,14 and
a 20% relative risk reduction in vascular events
defined as cardiovascular death, non-fatal MI and
stroke when taken in combination with aspirin,
compared with aspirin alone.15 Although combination
Fig. 2. Non-COX-1 mediated pathways of platelet activation. There are multiple non-COX1 mediated pathways of platelet
activation (indicated 1–3) that may account for aspirin resistance. COX1 inhibition of TXA2 production may be overcome by
movement of exogenous PGH2 into the affected platelet and its conversion to TXA2. Decreased COX1 based TXA2
production limits platelet activation via path 4, but persistent activation may occur via TXA2 produced via path 3.
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therapy was associated with a significant increase in
the risk of major bleeding (3.7% vs. 2.7%), there was no
difference in the risk of life-threatening bleeding or
haemorrhagic strokes.15
The beneficial effects of thienopyridines observed
may be multifactorial. Aspirin resistance secondary to
lack of compliance with aspirin medication and/or the
presence of TXA2 independent mediators of platelet
activation, such as thrombin and serotonin, have been
suggested as possible reasons (Fig. 2). Thrombin
mediated platelet activation may be important in this
patient group since serum fibrinogen levels and
thrombin generation are thought to be important in
pathophysiology of atherothrombosis.16 Other factors
such as high levels of ADP and collagen at sites of
atherothrombosis may also contribute to this observed
effect.17 Platelets from aspirin resistant subjects have
been found to be more sensitive to ADP18 and this may
contribute to the proposed advantage of clopidogrel.
Definition of aspirin resistance
In defining aspirin resistance, it is important to
distinguish clinical aspirin resistance to resistance
demonstrated by laboratory testing of platelet activity.
Clinical aspirin resistance, where patients suffer
atherothrombotic events despite the use of aspirin, is
a relatively common problem as demonstrated in the
PURSUIT trial.1 Some patients will suffer vascular
events in spite of adequate platelet inhibition due to
the severity of underlying arterial disease. The assess-
ment of aspirin resistance by laboratory methods is
potentially of greater therapeutic importance as their
results would allow identification of patients at risk of
clinical events and allow intervention to prevent
subsequent morbidity or mortality.
Laboratory definitions of aspirin resistance have
involved either detecting the failure of aspirin’s
pharmacological effect, or the failure of aspirin to
prevent inhibition of platelet aggregation. Aspirin
resistance, defined by its pharmacological action, is
persistent production of thromboxane A2 despite
therapy, measured by the presence of thromboxane
A2 metabolites in serum or urine.19 In contrast,
persistent platelet aggregation despite aspirin treat-
ment defines failure of aspirin mediated platelet
inhibition, and this may occur via non-thromboxane
mediated pathways of platelet activation. It has been
suggested that aspirin resistance is a misleading term
since in some situations, aspirin successfully inhibits
thromboxane synthesis but platelet aggregation per-
sists. The term aspirin ‘non-response’ encompasses the
failure of aspirin to both inhibit thromboxane syn-
thesis and reduce platelet aggregation.19 In an attempt
to clarify different patterns of aspirin resistance in
patients Weber et al.20 demonstrated three distinct
groups with regard to pharmacological behaviour
(Table 2). This relatively complex definition attempts
to objectively classify the difference between aspirin
resistance and aspirin non-response, but is limited to
collagen agonist based aggregometry as the method of
platelet function testing and is therefore associated
with limitations of this methodology.
Laboratory assessment of aspirin resistance is
problematic since definitions of aspirin resistance or
non-response vary according to the method of platelet
function testing employed. Different techniques define
levels of platelet aggregation in units that cannot be
directly compared.2 Definitions of aspirin resistance
within a particular technique are also subject to
variation. The setting of criteria defining aspirin
resistance is often arbitrary, and there is no standard
protocol in administering tests. Using the same
technique of optical aggregometry, Helgason et al.
and Gum et al. reported rates of complete aspirin
resistance of 75%21 and 5.5%,2 respectively. The
considerably different platelet aggregation criteria
and different concentration of agonists used for
platelet activation in the two studies probably con-
tributed to this disparity.
Definitions of aspirin resistance need to incorporate
an understanding of pathophysiological conditions
and outcomes to have clinical significance. Defining
aspirin resistance by assessing the inhibition of TXA2
production considers the pharmacological action of
aspirin but does not consider platelet aggregation,
which is arguably a more clinically relevant outcome.
Measurement of the metabolites of thromboxane A2 in
serum and urine, thromboxane B2 and urinary 11-
dehydro thromboxane B2, have been used extensively
to investigate aspirin resistance.19 However, urinary
11-dehydro TXB2 levels can be influenced by recent
acute thrombotic events such as MI or stroke which
may increase secretion and cause variation in the
levels of this urinary marker.19
Laboratory definitions of aspirin non-response
based on platelet function rather than the measure-
ments of metabolites, and preferably based on
techniques that are suitable for use and interpretation
in the wider medical community, are most likely to
have clinical utility. However, documentation of
laboratory defined aspirin non-response cannot be
presumed to have clinical significance before corre-
lation with patient outcomes is established. There is a
need to define levels of failure of platelet inhibition
that have high positive and negative predictive values
for subsequent clinical events.
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Incidence
Aspirin resistance has been detected by laboratory
methods in both healthy individuals22,23 as well as
those with vascular disease. Studies have variably
documented aspirin resistance in 5.5–60% of patients,
but platelet activation is notoriously difficult to study
and the variations are likely due to different methods
of platelet investigation, different definitions of aspirin
resistance and small sample sizes (Table 1).24 Failure of
aspirin effect may be more significant in those with
known cardiovascular disease (Table 2) since athero-
sclerosis is associated with a prothrombotic state.21,23,
25,26 In a prospective trial of patients with vascular
disease Gum et al.2 found that aspirin non-responders
and aspirin semi-responders were more likely to be
women, and tended to be older. Rates of aspirin
resistance were not affected by race, diabetes, platelet
count or presence of renal and hepatic disease.2
Smokers have raised fibrinogen levels27 and smoking
has been associated with an increased level of aspirin
resistance28 but these findings have not been consist-
ent.2
Mechanism
A mechanism of resistance has not been firmly
established, but is almost certainly multifactorial.
Issues such as inadequate dose and poor drug
compliance may contribute to the failure of aspirin to
inhibit platelet aggregation. Other factors contributing
to aspirin resistance can be classified into these three
broad groups:
Non-COX1 mediated pathways of platelet activation
Aspirin exerts its antiplatelet effect by blocking the
COX1 enzyme that produces the potent platelet
agonist TXA2 from arachidonic acid. Non-COX1
mediated pathways of platelet activation, such as
platelet activation mediated by serotonin and throm-
bin, may contribute to aspirin resistance (Fig. 2).
Persistent TXA2 production despite adequate
COX1 inhibition can occur via an alternative COX2
pathway, found in vascular endothelial cells (VECs)
and smooth muscle cells. COX2, which is strongly
induced in vascular disease25 is able to convert
arachidonic acid to prostaglandin H2 (PGH2) which
can be transported into platelets for the production of
TXA2.29,30 COX1 regeneration in nucleated cells such
as macrophages or VECs can also lead to persistent
TXA2 production.19,31
Increased levels of catecholamines associated with
stress and exercise have a significant prothrombotic
effect that may also contribute to apparent aspirin
resistance.
Increased platelet reactivity
Erythrocyte interactions with platelets, polymorph-
isms in the IIIa subunit of platelet GPIIb/IIIa recep-
tors, increased levels of prostaglandin F2a (PGF2a)
and increased platelet sensitivity to collagen may all
contribute to increased platelet reactivity and platelet
aggregation despite aspirin therapy.
Erythrocytes have been shown to induce the
production of factors by platelets that are central to
thrombus formation, including thromboxane B2,
serotonin, b-thromboglobulin and ADP.32,33
Carriers of the A2 polymorphism of the GP IIb/IIIa
fibrinogen receptor subunit have platelets that are
associated with enhanced thrombin formation and a
lower threshold for activation with alpha granule
release and fibrinogen binding.34 Such individuals are
therefore less responsive to the antithrombotic effects
of aspirin.34 This polymorphism is reported to have a
frequency of 20–30% in European populations.35
Other factors associated with increased platelet
reactivity include increased production of PGF2a, an
isoprostane that can amplify the response of human
platelets to agonists and cause vasoconstriction,36 and
an increased sensitivity of platelets in aspirin resistant
patients to low dose collagen, a physiological platelet
agonist.37
Increased platelet turnover
Increased platelet turnover in response to haemor-
rhage and surgical intervention may lead to the
generation of an increased fraction of platelets still
able to form thromboxane within the daily dosing
intervals.38
Measurement
Techniques that have been employed to investigate
aspirin resistance include bleeding time,22 whole
blood and platelet aggregometry,2,21,26 measurement
of platelet aggregation ratios,39 the platelet reactivity
index,24 thromboxane A2 metabolites,19 flow cytome-
try40 and PFA-100e.2,41,42 Different methods have
reported a wide range of estimates of aspirin resist-
ance in study populations with poor concordance
between different methods.2
There is growing evidence that constituents of
blood other than platelets and plasma are important
in the coagulation process, such as vascular endo-
thelial factors and shear stress. Production of nitric
oxide, an important inhibitor of platelet activation, by
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vascular endothelial cells (VECs) and aspirin inhi-
bition of endothelial prostacyclin production, a vaso-
dilator and platelet antiaggregant, cannot be
accounted for by ex vivo tests.21,43 Use of platelet rich
plasma in tests such as optical aggregometry cannot
account for the prothrombotic effects of erythrocyte–
platelet interactions, and may not accurately replicate
physiological platelet aggregation.
The PFA-100e is a promising technique for the
rapid assessment of aspirin resistance. Benefits of this
technique include ease of use, speed of analysis and
reproducibility of results.42,44 It also attempts to
replicate the shear stress found in vivo by passing the
sample of whole blood through a capillary tube (Fig.
3). These advantages enable the PFA-100e to be
widely used and rapidly interpreted outside tertiary
institutions, in contrast to aggregometric techniques.
PFA-100e has been found to be more sensitive than
optical aggregometry in detecting aspirin resistance.2
The need to accurately diagnose and monitor
treatment of aspirin resistance demands a test to be
rapid, reproducible, easily operated and interpreted,
and should involve the use of whole blood samples to
best replicate the physiological conditions of platelet
aggregation. Most platelet function techniques used in
researching aspirin resistance have limited clinical
application due to their complexity and cost, and
definitions of aspirin resistance and their clinical
utility are therefore limited. Potential point of care
techniques such as the PFA-100e are promising,41
with some studies suggesting that the technique may
assist in guiding dose of aspirin to account for inter
and intra-patient variability,45 but its insensitivity to
the action of thienopyridines may limit its use.46 Other
point of care techniques that may be promising but yet
to be used in researching aspirin resistance include the
Ultegra Rapid Platelet Function Assay (Accumetrics)47
and the Thromboelastogram.48
Dose of aspirin
Non-standardised doses of aspirin may contribute to
aspirin resistance. Current studies demonstrate that
80–325 mg of aspirin daily is both pharmacologically
effective at inhibiting 95% of COX149 and clinically
beneficial, with higher doses associated with a greater
incidence of gastrointestinal side effects without any
additional clinical benefit.8,50,51 However, ex vivo
studies of platelet function suggest that anti-aggrega-
tory effects of aspirin are dose dependent. An increase
in aspirin dosage from 325 to 1300 mg/day has been
shown to reduce rates of aspirin resistance from 25 to
8%.21 The reported difference may be related to theTa
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inhibition of COX2. While 95% of COX1 is inhibited by
80–325 mg of aspirin, inhibition of COX2 requires
doses of aspirin in excess of 500 mg daily.49 PGH2 can
be formed from COX2 conversion of arachidonic acid
(AA), and can be transported to platelets for the
production of TXA2 without platelet COX1. Higher
doses of aspirin may inhibit both COX1 and COX2,
inhibiting both possible sources of TXA2. Higher
doses of aspirin (500 mg) have also been shown to
inhibit the prothrombotic interactions between eryth-
rocytes and platelets.33 While aspirin dosage above
325 mg daily is probably inappropriate in clinical
practice, dose related changes in aspirin resistance
within recommended aspirin prescription guidelines
have also been observed in patients assessed by
aggregometry52 and assays of TXA2 metabolites.53
While there is no clinical evidence to suggest that
doses higher than 325 mg daily are beneficial,8 there is
a clear dose–response relationship between aspirin
and the inhibition of platelet function in ex vivo
laboratory tests, even within the usual range of 75–
325 mg which may contribute to the variability of
aspirin resistance rates reported.
These findings suggest that there may be some
benefit to increasing aspirin dosage based on lab tests
within the recommended range of 75–325 mg daily,
Table 2. Types of aspirin resistance20
Type I resistance Pharmacokinetic Platelet aggregability successfully inhibited by in vivo addition of
aspirin. This may be due to patient non-compliance or a range of
dose–response effect between patients
Type II resistance Pharmacodynamic Platelet aggregability continued when in vitro aspirin was added,
with the persistent formation of TXA2. This suggests that platelet
activation persists despite inhibition of COX1, possibly due to COX2
production of PGH2, which can be converted to TXA2. An
alternative explanation is defective COX1 binding of aspirin due to
polymorphisms in the gene encoding Ser529 or Arg120
Type III resistance Pseudoresistance Platelet aggregability was continued even when in vitro aspirin was
added, but there was successful inhibition of TXA2 formation. The
likely mechanisms are non-TX mediated pathways of thrombosis
and an increased sensitivity to collagen.37,38
Fig. 3. Platelet function analyser. Whole blood ‘flows’ through an aperture in a collagen/agonist membrane. A platelet plug
forms causing flow to stop. This is the outcome measure; closure time.
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but the clinical benefits of this are unclear. There is
currently no clinical indication for doses higher than
this range. In some circumstances, aspirin dosing
above the recommended range may be appropriate
due to either evidence of clinical or laboratory aspirin
resistance, but given the increasing morbidity related
to doses of aspirin higher than 325 mg daily, alterna-
tive antiplatelet therapy should be considered. More
work is needed to clarify the clinical significance of
dose dependent aspirin resistance, and given the
present circumstantial clinical correlation of aspirin
resistance and clinical outcomes, a recommendation to
change current practice is not appropriate.
Other factors affecting aspirin resistance
Aspirin resistance in the postoperative period
Increased platelet turnover may contribute to
inadequate inhibition of platelet aggregation in the
post-surgical patient treated with aspirin. Patients
receiving daily aspirin after coronary artery bypass
grafting showed only 30–50% inhibition of thrombox-
ane production compared to 94% in healthy volunteers
receiving the same dose of aspirin. The increased
platelet turnover in response to surgical intervention
may lead to the generation of an increased fraction of
platelets still able to form thromboxane within the
daily dosing intervals.38 Such patients may need more
frequent doses of antiplatelet medication to account
for increased platelet generation.
Aspirin resistance over time
Differences in platelet response with time on a fixed
dose of aspirin treatment has been reported by
Helgason et al.21 who found that some patients
changed from complete to partial platelet inhibition
during a constant dose of ASA over 6 months.
Andersen et al.41 found that 10% of patients converted
from aspirin responder to non-responder over 5
months follow-up. Variability in response can also be
measured on a shorter time scale with a larger effect of
aspirin at 2 h postdose compared to 12 and 24 h.24,39
This time dependent effect may also explain, in part,
the range of reported incidence of aspirin resistance.
Consideration needs to be given to the time after
administration of aspirin that analysis of platelet
function is performed. The variability of aspirin effect
over time may be relevant in the need for repeated
testing for aspirin resistance over months to ensure
long-term drug efficacy and continued protection
against ischaemic events.
Prothrombotic effects of exercise and catecholamine release
Increased levels of catecholamines associated with
stress and exercise have a significant prothrombotic
effect, and may be relevant in antagonising the
antiplatelet activity of aspirin in patients with athero-
sclerotic vascular disease. Catecholamine induced
platelet aggregation was not inhibited by aspirin
pretreatment of patients, despite adequate inhibition
at rest.54 Similarly in exercise, aspirin does not prevent
an exercise induced rise in platelet activation and
subsequent aggregation.55 In both exercise and stress,
the effect of serotonin release and shear induced
aggregation due to increased cardiac output and
changes in blood flow may combine with the increased
catecholamine release to create a prothrombotic
state.56,57 This may have bearing on the current advice
regarding exercise programs given to patients with
intermittent claudication and undergoing cardiac
rehabilitation. While exercise has undoubted benefits
in both patient groups close observation of response to
antiplatelet therapy may prove interesting.
Clinical impact of aspirin resistance
It is clear that clinically defined aspirin resistance is a
major concern, and there is growing evidence that
patients with laboratory evidence of aspirin resistance
are at a greater risk of thromboembolic events than
aspirin responders.19,26,58 To date there has been only
one prospective study associating suboptimal platelet
response to aspirin to a higher risk of adverse clinical
outcomes. In a 2-year follow up of 326 stable
cardiovascular patients from 1997 to 1999 on 325 mg
daily aspirin, 17 (5.2%) aspirin resistant patients
defined by optical aggregometry had an increased
risk of death, MI, or CVA compared with patients who
were aspirin sensitive (24% vs. 10%).58 However,
aggregometry has significant methodological limi-
tations and the small sample size studied likely
contributed to an inexact estimation of hazard ratio
suggested by the wide confidence interval reported
(hazard ratio 4.1, 95% CI 1.4–12.1).58 In a nested case
control study of 488 aspirin treated patients, signifi-
cantly higher concentrations of urinary thromboxane
A2 metabolites were found in patients suffering
cardiovascular events despite aspirin treatment com-
pared to age and sex matched controls who did not
suffer events.19 Patients in the upper quartile of
urinary metabolite concentration ðn ¼ 122Þ; suggesting
greater failure of aspirin in reducing TX synthesis, had
a two times higher risk of MI and a 3.5 times higher
risk of cardiovascular death.19 Retrospective analysis
of patients with prior atherosclerotic disease showed a
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34% aspirin non-responder rate by PFA-100e in
patients who had suffered a cerebrovascular event in
prior 24 months compared to 0% in asymptomatic
patients.59 In patients with POAD 60 of 100 patients
undergoing peripheral artery angioplasty demon-
strated inappropriate platelet inhibition after 100 mg
of aspirin, with these non-responders having an 87%
increased risk of arterial reocclusion during 2-year
follow-up.26 It is clear that further large prospective
studies are needed to further clarify the clinical
significance of aspirin resistance.
Some studies show statistically non-significant
differences in subsequent clinical outcomes. Andersen
et al. only demonstrated a tendency toward higher
event rates in the non-responders as compared to the
responders in 4 years follow up (36% vs. 24%)41 and
Buchanan et al.60 could not demonstrate a difference
between responders and non-responders in thrombo-
tic events after 2 years of follow up.
Conclusion
The current limitations in our understanding of
aspirin resistance are in part due to the difficulties in
assessing platelet function and aspirin resistance. A
lack of consensus on a definition of aspirin resistance,
variability on aspirin dosages between studies and the
use of numerous platelet assessment techniques each
with their own limitations, have all contributed to the
variable reporting of aspirin resistance. However, it is
clear that clinical aspirin resistance is a significant
problem. While aspirin resistance can be detected with
current laboratory techniques, a test with high positive
and negative predictive values for important clinical
end points remains elusive.
Developing a technique of platelet analysis that is
affordable, rapid, widely available, easily performed
and interpreted is a priority. The PFA-100e needs
further evaluation in the investigation of aspirin non-
response, and expansion on its current insensitivity to
thienopyridines which may limit its utility as a point
of care test. Prospective trials using and comparing
point of care testing techniques such as PFA and
TEG are needed to clarify the significance of clinical
outcomes associated with detected levels of aspirin
non-response. Standardising both the dose of
aspirin and the current array of tests for measuring
aspirin non-response is required to achieve consistent
results and allow further investigation of clinical
outcomes. Better detection of aspirin resistance will
allow improved investigation of the use and cost
effectiveness of other antiplatelet therapies in patients
with proven aspirin resistance.
Although there is no level 1 evidence on which to
recommend a change in clinical practice, antiplatelet
medication in patients suffering recurrent clinical
events while prescribed low dose aspirin may be
inadequate, and there may be a role for either
increasing the aspirin dose to the upper range of the
recommended 75–325 mg guide or prescribing an
alternative antiplatelet agent.
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